TMB-L

The study highlights a pro-metastatic ELANE + neutrophil subpopulation, with RELB acting as its primary transcriptional regulator. The RELB signature may serve as a biomarker for prognosis and treatment response prediction, indicating a potential target for precision treatment in EGFR wildtype LUAD.

Although Y is directly observed as log10 mutation frequency in LTEE, in tumors Y can represent a longitudinally measurable phenotypic state (e.g., drug-tolerance scores from single-cell data, MRD/VAF-derived burden proxies, or pathway activity states). The balance between stabilizing strength (θ) and stochastic variability (σ) provides a quantitative axis governing plasticity and persistence, motivating future calibration to clinical longitudinal data for evolution-aware, patient-specific modeling.

Clinically significant mutations (KIT: Asp816Val, Ala829Pro; and KRAS: Gln61Leu) suggest potential therapeutic targets for GCT, while MTOR, PIK3CA, and AKT2 emerge as candidates for targeted therapy. These findings provide insights into the genomic alterations of pediatric GCTs and emphasize the potential for targeted therapies.

We provide an overview of the current checkpoint inhibitor landscape for pediatric brain tumors, highlight barriers and summarize possible approaches that can be efficaciously explored in future clinical trials.

In summary, nanotechnology provides a promising strategy to improve both the efficacy and specificity of targeted therapies in LCINS. Successful clinical translation will depend on biologically aligned carrier-payload combinations, scalable and reproducible manufacturing processes, and biomarker-guided patient selection.

In this review, we provide a comprehensive overview of current therapeutic strategies for HCC, with particular emphasis on immunotherapeutic approaches. We discuss common clinical challenges spanning diagnosis to treatment resistance, critically evaluate key clinical trial outcomes, and highlight future directions aimed at improving therapeutic efficacy and long-term disease control.

The patient was started on mitotane and metyrapone, followed by 8 cycles of etoposide-doxorubicin-cisplatin plus mitotane. The patient underwent complete surgical resection, achieving full remission. More than 1 year later, she remains disease free.

A multifactorial cause is suspected. Chronic gingivostomatitis, immunosuppression, and/or viral infection may be associated with FOSCC in young cats.

Of these agents, Telomelysin (OBP-301, Suratadenoturev), a telomerase-specific oncolytic adenovirus, demonstrated clinical safety but limited efficacy in refractory tumors. Given its multifaceted antitumor functions and ability to overcome key barriers in pancreatic cancer, OBP-702 represents a highly promising therapeutic candidate. A first-in-human clinical trial evaluating endoscopic ultrasonography-guided intratumoral injection of OBP-702 is currently in preparation, expected to advance clinical translation of this novel virotherapeutic strategy.

Here, we report the successful generation and expansion of TIL engineered with regulatable, membrane-bound IL15 (cytoTIL15™ cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2...Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

Drug sensitivity analysis identified Doramapimod, a MAPK inhibitor, which combined with anti-PD-1 therapy significantly enhanced tumor regression in mouse models by reducing Treg infiltration. In conclusion, this study establishes IGSF9 as a prognostic and predictive biomarker for immunotherapy resistance in CC and suggests that targeting IGSF9-associated KRAS/MAPK pathways with Doramapimod may offer a novel combination strategy to overcome TME-mediated resistance, warranting further clinical investigation for personalized CC treatment.

Early-phase trials combining these approaches in MSS CRC show encouraging activity, while neoadjuvant and adjuvant immunotherapy in MSI-H disease redefines treatment paradigms, with some patients achieving complete responses without surgery. This review synthesizes the current evidence and emerging innovations in CRC immunotherapy and proposes a structured translational framework to extend immunotherapy benefits beyond the MSI-H subset.